Regencell Bioscience Holdings Limited Ordinary Shares (RGC) is a publicly traded Healthcare sector company. As of July 26, 2026, RGC trades at $5.72 with a market cap of $2.83B and a P/E ratio of 7.92. RGC moved +1.07% today. Year to date, RGC is -72.76%; over the trailing twelve months it is -62.32%. Its 52-week range spans $0.09 to $83.60. Rallies surfaces RGC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Regencell (RGC) pops as traders revisit newly filed $500M ATM share-sale program: Regencell Bioscience Holdings (RGC) is higher as traders continue to react to the company’s new at-the-market equity program that allows sales of up to $500 million in ordinary shares. The setup, filed March 30, 2026, keeps financing and potential dilution in focus while the stock trades with elevated volatility.
| Metric | Value |
|---|---|
| Price | $5.72 |
| Market Cap | $2.83B |
| P/E Ratio | 7.92 |
| EPS | $0.72 |
| Dividend Yield | 0.22% |
| 52-Week High | $83.60 |
| 52-Week Low | $0.09 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $3.16B |
| Net Income | $112.30M |
| Gross Margin | 0.00% |
RGC analyst coverage data. Average price target: $0.00.